Search research articles
Contact Us
Filters
Showing results (81-90 of 88) with videos related to
Page
of 9
Sort By:
You have reached the last page of results.
This site can display upto 88 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 21, 2019
First-in-Human Phase I Clinical Trial of Pharmacologic Ascorbate Combined with Radiation and Temozolomide for Newly Diagnosed Glioblastoma
Bryan G Allen, Kellie L Bodeker, Mark C Smith, et al.
Redox Biology
|
December 1, 2020
Magnetic resonance imaging (MRI) of pharmacological ascorbate-induced iron redox state as a biomarker in subjects undergoing radio-chemotherapy
Cameron M Cushing, Michael S Petronek, Kellie L Bodeker, et al.
Redox Biology
|
May 7, 2022
Pharmacological ascorbate improves the response to platinum-based chemotherapy in advanced stage non-small cell lung cancer
Muhammad Furqan, Taher Abu-Hejleh, Laura M Stephens, et al.
Lancet (London, England)
|
November 15, 2024
Safety and efficacy of pembrolizumab, radiation therapy, and surgery versus radiation therapy and surgery for stage III soft tissue sarcoma of the extremity (SU2C-SARC032): an open-label, randomised clinical trial
Yvonne M Mowery, Karla V Ballman, Angela M Hong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 29, 2023
Magnetic Resonance Imaging of Iron Metabolism with T2* Mapping Predicts an Enhanced Clinical Response to Pharmacologic Ascorbate in Patients with GBM
Michael S Petronek, Varun Monga, Kellie L Bodeker, et al.
Cancer Cell
|
April 4, 2017
O<sub>2</sub><sup>⋅-</sup> and H<sub>2</sub>O<sub>2</sub>-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate
Joshua D Schoenfeld, Zita A Sibenaller, Kranti A Mapuskar, et al.
Cancer Cell
|
August 16, 2017
O<sub>2</sub><sup>⋅-</sup> and H<sub>2</sub>O<sub>2</sub>-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate
Joshua D Schoenfeld, Zita A Sibenaller, Kranti A Mapuskar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 26, 2022
Alliance A071401: Phase II Trial of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic <i>NF2</i> Mutations
Priscilla K Brastianos, Erin L Twohy, Elizabeth R Gerstner, et al.
Page
of 9
Search research articles
Search
Showing results (81-90 of 88) with videos related to
Sort By:
Page
of 9
You have reached the last page of results.
This site can display upto 88 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 21, 2019
First-in-Human Phase I Clinical Trial of Pharmacologic Ascorbate Combined with Radiation and Temozolomide for Newly Diagnosed Glioblastoma
Bryan G Allen, Kellie L Bodeker, Mark C Smith, et al.
Redox Biology
|
December 1, 2020
Magnetic resonance imaging (MRI) of pharmacological ascorbate-induced iron redox state as a biomarker in subjects undergoing radio-chemotherapy
Cameron M Cushing, Michael S Petronek, Kellie L Bodeker, et al.
Redox Biology
|
May 7, 2022
Pharmacological ascorbate improves the response to platinum-based chemotherapy in advanced stage non-small cell lung cancer
Muhammad Furqan, Taher Abu-Hejleh, Laura M Stephens, et al.
Lancet (London, England)
|
November 15, 2024
Safety and efficacy of pembrolizumab, radiation therapy, and surgery versus radiation therapy and surgery for stage III soft tissue sarcoma of the extremity (SU2C-SARC032): an open-label, randomised clinical trial
Yvonne M Mowery, Karla V Ballman, Angela M Hong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 29, 2023
Magnetic Resonance Imaging of Iron Metabolism with T2* Mapping Predicts an Enhanced Clinical Response to Pharmacologic Ascorbate in Patients with GBM
Michael S Petronek, Varun Monga, Kellie L Bodeker, et al.
Cancer Cell
|
April 4, 2017
O<sub>2</sub><sup>⋅-</sup> and H<sub>2</sub>O<sub>2</sub>-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate
Joshua D Schoenfeld, Zita A Sibenaller, Kranti A Mapuskar, et al.
Cancer Cell
|
August 16, 2017
O<sub>2</sub><sup>⋅-</sup> and H<sub>2</sub>O<sub>2</sub>-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate
Joshua D Schoenfeld, Zita A Sibenaller, Kranti A Mapuskar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 26, 2022
Alliance A071401: Phase II Trial of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic <i>NF2</i> Mutations
Priscilla K Brastianos, Erin L Twohy, Elizabeth R Gerstner, et al.
Page
of 9